What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Rivercell
Builds the data engine and AI world model that predict how human cells respond to treatment.
What they do
Rivercell produces interventional, time-resolved, multimodal single-cell data at scale in its own automated wet lab and uses it to train an AI world model of the cell. Launched on October 7, 2026 with a $25 million seed round led by HV, with HCVC, Alven and Bpifrance Digital Venture participating.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI virtual cell
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- Paris, France
- Region
- Europe
- Founded
- 2025
- Total funding
- $25M raised
Notable investors: HV Capital, HCVC, Alven, Bpifrance Digital Venture.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA
Dismantling the 25-Year R-CHOP Monopoly: Frontline Bispecifics and the Future of Lymphoma
Dr. Dereck Mush, MD, MBA
CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
Dr. Dereck Mush, MD, MBA